@FiercePharma: ICYMI: PATH Malaria Vaccines Initiative nets $156 million from Gates Foundation. FierceVaccines story | Follow @FiercePharma
@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Here's a first: Regeneron cuts forecast after hard-charging Eylea sales miss. Article | Follow @CarlyHFierce
> Denmark's Lundbeck saw profits decline as generics erode sales of older meds and the company plows money into new product launches. Report
> Endo International ($ENDP) posted a 16% revenue hike for the third quarter, thanks in part to new acquisitions, and raised its earnings forecast for the year. Release
> The FDA is boosting the size of its China office, adding new inspectors to check out food and drugs destined for the U.S. market. Report
> The FDA slapped new warnings about antibiotic-associated diarrhea and drug interactions onto a class of stomach drugs known as proton pump inhibitors, three years after an advocacy group started lobbying for the change. Report
> Ironwood Pharmaceuticals ($IRWD) said its new gastrointestinal drug Linzess saw prescriptions grow by 22% for the third quarter. Release
> Merck KGaA's pharma CEO Stefan Oschmann was elected to serve as president of the International Federation of Pharmaceutical Manufacturers and Associations, replacing Eli Lilly ($LLY) chief John Lechleiter. Release
> Actavis CFO R. Todd Joyce will retire early next year, but will stay in his post until the company finds his replacement. Release
Medical Device News
@FierceMedDev: ICYMI yesterday: Spinoff Halyard Health gets boost from Ebola fears, stock up modestly in market debut. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Maryland provides seed financing to 15 med tech startups. Item | Follow @VarunSaxena2
@EmilyWFierce: This just in from the $ACT earnings call: "Actergan." | Follow @EmilyWFierce
> Former Boston Scientific engineer charged with intellectual theft. More
> Cantel Medical buys Italian healthcare manufacturer for $24.5M. News
Biotech News
@FierceBiotech: Novartis gears up for FDA scrutiny with a new blood cancer drug. Report | Follow @FierceBiotech
@JohnCFierce: Should Chris Viehbacher replace John Lechleiter at $LLY? Now that would be interesting. | Follow @JohnCFierce
@DamianFierce: The most metal researcher in all of science. More | Follow @DamianFierce
@EmilyMFierce: Science Cafés are growing in popularity. More | Follow @EmilyMFierce
> GlaxoSmithKline heads to the FDA with its next big respiratory bet. Report
> AstraZeneca's $2B oncology contender shows promise in prostate cancer. Article
> Can Rockwell Medical win FDA approval for its dialysis drug? More
Drug Delivery News
> Distinct, compartmental reactions in an 'artificial cell' offer controlled delivery action. More
> OptiNose submits NDA to FDA. Item
> MIT spinoff SQZ Biotech nabs startup prizes for cell-squeezing delivery enhancer. Story
> AstraZeneca, University of Manchester create new center for advanced drug delivery. Article
> Study: Timing of administration an oft-overlooked factor in drug delivery. More
Diagnostics News
> Diagnostics companies homing in on rapid mobile tests to quell Ebola outbreak. Report
> Myriad signs expanded deal with AbbVie for cancer Dx. More
> AstraZeneca shells out $150M for cancer Dx outfit Definiens. Item
> LabCorp bets $6B in diversification deal with Covance. Story
> Qiagen beats the Street's Q3 numbers with success of companion Dx and next-gen TB test. Article
Pharma Marketing News
> Who's king of the orphan drug hill? BMS, Merck, Celgene and Roche, to name a few. Article
> A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing? More
> Sovaldi's not the only superhero launch: Meet the rest of the pharma Avengers. Story
> Sales speedster Eylea faces a tougher track in new DME market, Regeneron SVP says. Article
And Finally ... With a year of tough endurance training, sedentary folks can achieve the heart benefits accorded to elite athletes. Report (sub. req.)